Company Filing History:
Years Active: 2024
Title: Charles R Allerson: Innovator in Hepatitis C Treatment
Introduction
Charles R Allerson is a notable inventor based in San Diego, CA. He has made significant contributions to the field of antiviral therapies, particularly in the treatment of hepatitis C virus (HCV). His innovative work focuses on the development of modified oligonucleotides that target specific viral mechanisms.
Latest Patents
Allerson holds a patent for "Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect." This patent describes compositions and methods for inhibiting miR-122 activity, which is crucial in the context of HCV infection. The compositions feature nucleoside modifications that enhance their potency as inhibitors and include moieties that facilitate liver delivery. These advancements may provide effective treatment options for individuals infected with hepatitis C virus.
Career Highlights
Throughout his career, Allerson has worked with prominent organizations, including Regulus Therapeutics Inc. and the University of Texas System. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Allerson has collaborated with notable colleagues such as Steven S Neben and Timothy Wright. Their combined expertise has furthered the development of innovative solutions in antiviral therapies.
Conclusion
Charles R Allerson's contributions to the field of hepatitis C treatment through his patented innovations highlight his role as a key inventor in the medical research community. His work continues to pave the way for advancements in antiviral therapies.